ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Post author: Post published:April 20, 2026 Post category: Continue ReadingACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Post author: Post published:April 20, 2026 Post category: Continue ReadingHumanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer Post author: Post published:April 20, 2026 Post category: Continue ReadingCCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingSafety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies Post author: Post published:April 20, 2026 Post category: Continue ReadingFeasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter’s Transformation Post author: Post published:April 20, 2026 Post category: Continue ReadingLisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter’s Transformation
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL Post author: Post published:April 20, 2026 Post category: Continue ReadingBAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer Post author: Post published:April 20, 2026 Post category: Continue ReadingIntra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
